Dr. Faulk is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
13001 E 17th Pl
Aurora, CO 80045Phone+1 303-724-6031
Education & Training
University of ColoradoFellowship, Pediatric Hematology/Oncology, 2015 - 2018- University of ColoradoResidency, Pediatrics, 2012 - 2015
- University of Colorado School of Medicine Anschutz Medical CampusClass of 2012
Certifications & Licensure
CO State Medical License 2015 - 2025
NM State Medical License 2021 - 2025
WY State Medical License 2024 - 2025- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia Start of enrollment: 2021 Nov 15
Roles: Principal Investigator, Contact
- Expanded Access Program for Revumenib
Roles: Contact
Publications & Presentations
PubMed
- 30 citationsAssessment of enrollment characteristics for Children’s Oncology Group (COG) upfront therapeutic clinical trials 2004-2015Kelly Faulk, Amy Anderson-Mellies, Myles Cockburn, Adam L. Green
Plos One. 2020-04-23 - 9 citationsPulmonary toxicity in paediatric patients with relapsed or refractory Hodgkin lymphoma receiving brentuximab vedotinKelly Faulk, Jenna Sopfe, Kristen Campbell, Deborah R. Liptzin, Arthur K. Liu
British Journal of Haematology. 2018-10-01 - 11 citationsThe safety of SARS-CoV-2 vaccines in persons with a known history of pegaspargase allergy: A single institution experience.Cassandra Rush, Kelly E Faulk, Zanette Kanani Bradley, Aubree Turner, Maija Krumins
The Journal of Allergy and Clinical Immunology. in Practice. 2022-02-01
Journal Articles
- Pulmonary Toxicity in Paediatric Patients with Relapsed or Refractory Hodgkin Lymphoma Receiving Brentuximab VedotinJenna M Sopfe, Kelly E Faulk, Arthur K Liu, Deborah R Liptzin, Carrye R Cost, British Journal of Haematology
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
